ResMed Inc. stock slips as Astral halt and GLP-1 worries weigh on sentiment

ResMed Inc. stock (ISIN US7611521078) recently changed hands near USD 228.25 as of early September 8, 2026, leaving the medical device maker below consensus analyst targets around USD 240 while investors weigh operational headwinds and a higher dividend against its latest fiscal 2026 results.MarketBeat

Stock retreats despite dividend and FY26 growth

According to market data summarized by MarketBeat, ResMed stock opened at USD 228.25 on September 8, 2026, with a 52-week range between USD 180.26 and USD 284.87, placing the current level roughly USD 48 below the recent year high and about USD 48 above the year low.

Intraday commentary from TradingKey reported that ResMed shares were down 3.15 percent on September 8, 2026, underperforming a 1.81 percent decline in the broader healthcare services and equipment sector as traders reacted to ongoing concerns over product disruptions and profitability.

Astral sales halt and GLP-1 concerns pressure valuation

Market analysis from TradingKey notes that ResMed has faced selling pressure after temporarily halting sales of its Astral ventilator product line to implement on-site safety measures, a move that is adding unexpected operating costs and diluting earnings per share in the near term.

The same report highlights that investor sentiment toward the stock remains sensitive to worries that GLP-1 weight-loss drugs could reduce the incidence or severity of obstructive sleep apnea, while the potential for a rival respiratory-device maker such as Philips to re-enter the market continues to weigh on sector valuations.TradingKey

Research commentary cited by Motley Fool Australia indicates that CPAP device demand remains robust and argues that fears about GLP-1 therapies structurally shrinking ResMed’s addressable market may be overstated, with analysts pointing out that real-world data suggest many GLP-1 users still initiate and remain on CPAP therapy.

FY26 results show double-digit growth

In its fiscal year 2026, which was most recently reported prior to September 8, 2026, ResMed increased revenue by 10 percent to USD 5.65 billion, while non-GAAP earnings per share rose 17 percent to USD 11.17, underscoring that the business is still growing despite margin headwinds.Motley Fool Australia

The same figures imply that profitability expanded faster than sales in FY26, which can support the investment case for ResMed if the company manages to control incremental costs from safety actions and portfolio adjustments while maintaining pricing power in its core sleep and respiratory devices.Motley Fool Australia

According to an institutional-flow overview from MarketBeat, large investors such as HSBC Holdings, Wellington Management and the Saudi Central Bank have added to their positions in ResMed in recent quarters, contributing to institutional ownership of about 55 percent and signaling continued long-term confidence despite short-term volatility.

Dividend increase and capital allocation moves

ResMed has also raised its quarterly dividend to USD 0.66 per share, equivalent to USD 2.64 per share on an annualized basis, which translates into a dividend yield of roughly 1.2 percent at a share price near USD 228 as of early September 2026.MarketBeat

Per an income-focused review from Motley Fool Australia, the most recent quarterly dividend of USD 0.66 per share was converted into approximately 0.0928 Australian dollars per CDI for ResMed’s Australian listing, illustrating how currency moves influence cash returns for non-US investors even when the underlying dividend is declared in US dollars.

A sector update summarized by The Globe and Mail points out that ResMed has been using proceeds from portfolio optimization, including the completed sale of its MatrixCare assets, along with buyback authorizations to adjust its share count and support returns, with CDIs on issue reported at about 581.1 million in August 2026 compared with 591.3 million a month earlier.

Analyst views and valuation backdrop

Consensus data compiled by MarketBeat show that ResMed carries an overall Hold rating from covering analysts, with six Buy recommendations and ten Hold ratings and an average 12-month price target of USD 240.31, which stands modestly above the recent trading level near USD 228.25.

A separate valuation note from MCH Advisory estimates that at a share price of USD 228 on September 8, 2026, ResMed trades at roughly 19 times forward earnings, a multiple that already embeds a meaningful probability that GLP-1 therapies lead to a lasting reduction in the pool of patients requiring CPAP devices.

For investors, this setup means that any evidence showing sleep-apnea prevalence or treatment adherence holding up despite wider GLP-1 adoption could prompt a re-rating from these levels, while negative surprise on volumes or margins could push the valuation closer to typical medtech peers.

Product focus: CPAP and cloud-connected systems

ResMed is best known for its portfolio of CPAP devices and masks that treat obstructive sleep apnea, complemented by cloud-connected software platforms that allow clinicians to remotely monitor patient usage and adjust therapy settings for better outcomes.MarketBeat

Analysts cited by Motley Fool Australia emphasize that ResMed’s investments in diagnostic and referral channels, including digital tools that streamline the path from suspected sleep apnea to confirmed diagnosis and treatment initiation, are designed to support long-term unit growth even in a more competitive environment.

ResMed stock and investor takeaway

With ResMed stock trading around USD 228.25 on its primary US listing as of September 8, 2026, compared with a 52-week high near USD 284.87 and an average analyst target of about USD 240, the shares currently sit below prior peaks but still carry expectations for continued earnings expansion and disciplined capital allocation.MarketBeat

More news and analyses on ResMed Inc. stock